GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » LT-Debt-to-Total-Asset

VIVUS (STU:VIU1) LT-Debt-to-Total-Asset : 0.28 (As of Mar. 2020)


View and export this data going back to . Start your Free Trial

What is VIVUS LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. VIVUS's long-term debt to total assests ratio for the quarter that ended in Mar. 2020 was 0.28.

VIVUS's long-term debt to total assets ratio declined from Mar. 2019 (1.02) to Mar. 2020 (0.28). It may suggest that VIVUS is progressively becoming less dependent on debt to grow their business.


VIVUS LT-Debt-to-Total-Asset Historical Data

The historical data trend for VIVUS's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS LT-Debt-to-Total-Asset Chart

VIVUS Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.76 0.87 0.98 0.27

VIVUS Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.02 0.38 0.26 0.27 0.28

VIVUS LT-Debt-to-Total-Asset Calculation

VIVUS's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2019 is calculated as

LT Debt to Total Assets (A: Dec. 2019 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2019 )/Total Assets (A: Dec. 2019 )
=53.391/196.477
=0.27

VIVUS's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2020 is calculated as

LT Debt to Total Assets (Q: Mar. 2020 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2020 )/Total Assets (Q: Mar. 2020 )
=53.675/195.397
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VIVUS  (STU:VIU1) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


VIVUS LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of VIVUS's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


VIVUS (STU:VIU1) Business Description

Traded in Other Exchanges
N/A
Address
900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008
VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines